CD155 and TIGIT expression has been correlated with significantly shorter overall and progression-free survival (PFS) in lung adenocarcinoma [26], and CD155 additionally has demonstrated this in small-cell lung cancer (SCLC) [27]. Here, PVR is linked to lung adenocarcinoma.